Jump to content

RG-7351: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Submitting using AfC-submit-wizard
Cat.
 
(8 intermediate revisions by 6 users not shown)
Line 1: Line 1:
{{Short description|TAAR1 agonist}}
{{Short description|TAAR1 agonist}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Draft topics|chemistry|medicine-and-health}}
{{AfC topic|stem}}
{{AfC submission|||ts=20241020042420|u=76.174.0.57|ns=118}}
{{AfC submission|t||ts=20241020042226|u=76.174.0.57|ns=118|demo=}}<!-- Important, do not remove this line before article has been created. -->
{{Infobox drug
{{Infobox drug
| drug_name =
| drug_name =
Line 65: Line 62:
}}
}}


'''RG-7351''' is a [[trace amine-associated receptor 1]] (TAAR1) [[partial agonist]] that is or was under development for the treatment of [[major depressive disorder]].<ref name="AdisInsight">{{cite web | title=RG 7351 | website=AdisInsight | date=5 November 2023 | url=https://adisinsight.springer.com/drugs/800031597 | access-date=20 October 2024}}</ref><ref name="Synapse">{{cite web | title=Delving into the Latest Updates on RG-7351 with Synapse | website=Synapse | date=19 September 2024 | url=https://synapse.patsnap.com/drug/aa992ac0fafe4f1f910bfb5ec30ec234 | access-date=20 October 2024}}</ref><ref name="LiuLi2018">{{cite journal | vauthors = Liu JF, Li JX | title = TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg | journal = Front Pharmacol | volume = 9 | issue = | pages = 279 | date = 2018 | pmid = 29636691 | pmc = 5881156 | doi = 10.3389/fphar.2018.00279 | url = }}</ref><ref name="WuLiuLi2022">{{cite journal | vauthors = Wu R, Liu J, Li JX | title = Trace amine-associated receptor 1 and drug abuse | journal = Adv Pharmacol | volume = 93 | issue = | pages = 373–401 | date = 2022 | pmid = 35341572 | pmc = 9826737 | doi = 10.1016/bs.apha.2021.10.005 | url = }}</ref> It reached [[Phases of clinical research#Phase I|phase 1]] [[clinical trial]]s for this indication in 2010.<ref name="AdisInsight" /><ref name="Synapse" /><ref name="WuLiuLi2022" /> However, as of November 2023, no further recent development has been reported since July 2016.<ref name="AdisInsight" /> The drug was developed by [[Hoffmann-La Roche]].<ref name="AdisInsight" /><ref name="Synapse" /><ref name="WuLiuLi2022" />
'''RG-7351''' is a [[trace amine-associated receptor 1]] (TAAR1) [[partial agonist]] that is or was under development for the treatment of [[major depressive disorder]].<ref name="AdisInsight">{{cite web | title=RG 7351 | work = AdisInsight | publisher = Springer Nature Switzerland AG | date=5 November 2023 | url=https://adisinsight.springer.com/drugs/800031597 | access-date=20 October 2024}}</ref><ref name="Synapse">{{cite web | title=Delving into the Latest Updates on RG-7351 with Synapse | website=Synapse | date=19 September 2024 | url=https://synapse.patsnap.com/drug/aa992ac0fafe4f1f910bfb5ec30ec234 | access-date=20 October 2024}}</ref><ref name="LiuLi2018">{{cite journal | vauthors = Liu JF, Li JX | title = TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg | journal = Frontiers in Pharmacology | volume = 9 | issue = | pages = 279 | date = 2018 | pmid = 29636691 | pmc = 5881156 | doi = 10.3389/fphar.2018.00279 | doi-access = free }}</ref><ref name="WuLiuLi2022">{{cite book | vauthors = Wu R, Liu J, Li JX | title = Behavioral Pharmacology of Drug Abuse: Current Status | chapter = Trace amine-associated receptor 1 and drug abuse | series = Adv Pharmacol | volume = 93 | pages = 373–401 | date = 2022 | pmid = 35341572 | pmc = 9826737 | doi = 10.1016/bs.apha.2021.10.005 | isbn = 978-0-323-91526-7 | chapter-url = }}</ref> It reached [[Phases of clinical research#Phase I|phase 1]] [[clinical trial]]s for this indication in 2010.<ref name="AdisInsight" /><ref name="Synapse" /><ref name="WuLiuLi2022" /> However, as of November 2023, no further recent development has been reported since July 2016.<ref name="AdisInsight" /> The drug was developed by [[Hoffmann-La Roche]].<ref name="AdisInsight" /><ref name="Synapse" /><ref name="WuLiuLi2022" />


==See also==
== See also ==
* [[Ralmitaront]] (RG-7906; RO-6889450)
* [[Ralmitaront]] (RG-7906; RO-6889450)
* [[RG-7410]]
* [[Ulotaront]] (SEP-363856; SEP-856)
* [[Ulotaront]] (SEP-363856; SEP-856)


==References==
== References ==
{{Reflist}}
{{Reflist}}



{{TAAR ligands}}
{{TAAR ligands}}


[[Category:Drugs with undisclosed chemical structures]]
[[Category:Experimental antidepressants]]
[[Category:Experimental antidepressants]]
[[Category:TAAR1 agonists]]
[[Category:TAAR1 agonists]]
[[Category:TAAR1 antagonists]]




{{Nervous-system-drug-stub}}
{{Pharma-stub}}

Latest revision as of 11:31, 19 December 2024

RG-7351
Clinical data
Other namesRG7351
Drug classTrace amine-associated receptor 1 (TAAR1) partial agonist

RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.[1] The drug was developed by Hoffmann-La Roche.[1][2][4]

See also

[edit]

References

[edit]
  1. ^ a b c d "RG 7351". AdisInsight. Springer Nature Switzerland AG. 5 November 2023. Retrieved 20 October 2024.
  2. ^ a b c "Delving into the Latest Updates on RG-7351 with Synapse". Synapse. 19 September 2024. Retrieved 20 October 2024.
  3. ^ Liu JF, Li JX (2018). "TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg". Frontiers in Pharmacology. 9: 279. doi:10.3389/fphar.2018.00279. PMC 5881156. PMID 29636691.
  4. ^ a b c Wu R, Liu J, Li JX (2022). "Trace amine-associated receptor 1 and drug abuse". Behavioral Pharmacology of Drug Abuse: Current Status. Adv Pharmacol. Vol. 93. pp. 373–401. doi:10.1016/bs.apha.2021.10.005. ISBN 978-0-323-91526-7. PMC 9826737. PMID 35341572.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=RG-7351&oldid=1263919728"